MedTrace Logo

Thromboprophylaxis After Surgery for Gynecologic Malignancy in China

NCT02935530 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 315

Last updated 2019-05-14

No results posted yet for this study

Summary

Venous thromboembolism (VTE) is an important cause of post-operative morbidity and mortality in women undergoing surgery for gynecologic malignancies. Although the benefit of thromboprophylaxis in reduction of post-operative VTE events after surgery for gynecologic cancers has been well documented around the world, the evidence for Chinese women is rare. The investigators designed this prospective and randomized study to assess the benefit of pharmacologic prophylaxis for patients received surgical treatment for gynecologic malignancies in China.

Conditions

  • Gynecologic Neoplasms
  • Venous Thromboembolism
  • Low Molecular Weight Heparin
  • Argatroban

Interventions

DRUG

s-LMWH

2125KU, subcutaneous injection of 5-10 days

DRUG

LMWH

4250KU, subcutaneous injection of 5-10 days

DRUG

Argatroban

20mg, injection for 5-10 days

Sponsors & Collaborators

  • Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Ding Ma, M.D. · Tongji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-08-31
Completion
2017-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02935530 on ClinicalTrials.gov